Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 4
Submit an article Journal homepage
82
Views
7
CrossRef citations to date
0
Altmetric
Review

Novel delivery methods for treatment of viral hepatitis: an update

Lucija Virovic University of Connecticut Health Center, Department of Medicine/GI Division, Room AM 044, 263 Farmington Avenue, Farmington, CT 06030-1845, USA. [email protected]
,
Catherine H Wu University of Connecticut Health Center, Department of Medicine/GI Division, Room AM 044, 263 Farmington Avenue, Farmington, CT 06030-1845, USA. [email protected]
,
Masayoshi Konishi University of Connecticut Health Center, Department of Medicine/GI Division, Room AM 044, 263 Farmington Avenue, Farmington, CT 06030-1845, USA. [email protected]
&
George Y Wu University of Connecticut Health Center, Department of Medicine/GI Division, Room AM 044, 263 Farmington Avenue, Farmington, CT 06030-1845, USA. [email protected]
Pages 707-717 | Published online: 11 Aug 2005

Bibliography

  • LAVANCHY D: Hepatitis B virus epidemiology disease burden, treatment, and current and emerging prevention and control measures. J. Viral. Hepat. (2004) 11(3):97–107.
  • REISS G, KEEFFE EB: Review article: hepatitis vaccination in patients with chronic liver disease. Aliment. PharmacoL Ther. (2004) 19(7):715–727.
  • YEN TSB: Regulation of hepatitis B virus gene expression. Semin Wrol (1993) 4:33–42.
  • •Review of HBV replication.
  • WRIGHT TL: Treatment hepatitis B: the state of the art. In: Clinical Care Options for Hepatitis. JP Phair (Ed.), iMedOptions, Reston, VA, USA (2003):168.
  • LOK ASF: New treatment of chronic hepatitis B. Semin. Liv. Dis. (2004) 4\(Suppl. 0:77–82.
  • ••Review of new HBV therapies.
  • BARTENSCHLAGER R, LOHMANN V: The hepatitis C virus. Baillieres Best Pract. Res. Clin. Gastroenterol (2000) 14(2):241–254.
  • •Classic review of HCV replication.
  • ROSENBERG S: Recent advances in the molecular biology of hepatitis C virus. J. Md. Bid. (2002) 313:451–464.
  • ••Review of HCV replication and interactions of the genome with viral proteins.
  • NIH consensus statement on management hepatitis C: 2002. NIH Consens. State Sci. Statements (2002) 19(3):1–46.
  • FOSTER GR: Past, present and future hepatitis C treatments. Semin. Liver Dis. (2004) 24\(Suppl. 2):97–104.
  • ZEIN CO, ZEIN NN: Advances in therapy for hepatitis C infection. Microbes Infec. (2002) 4:1237–1246.
  • •Review of new HCV therapies.
  • MCHUTCHISON JG, PATEL K: Future therapy of hepatitis C. Hepato/ogy (2002) 36(5 Suppl. 1):S245–S252.
  • ••A comprehensive review on drugdevelopment for hepatitis C.
  • WU GY, WU CH: Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. (1987) 262(10):4429–4432.
  • •First published report of receptor-mediated DNA delivery in vitro.
  • WU GY, WILSON JM, SHALABY F, GROSSMAN M, SHAFRITZ DA, WU CH: Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J. Biol. Chem. (1991) 266(22):14338–14342.
  • •First report of receptor-mediated gene delivery to liver in vivo.
  • WU GY, ZHAN P, SZE LL, ROSENBERG AR, WU CH: Incorporation of adenovirus into a ligand-based DNA carrier system results in retention of original receptor specificity and enhances targeted gene expression. J. Biol. Chem. (1994) 269(15):11542–11546.
  • •Interesting improvement of viral and receptor-mediated delivery to the liver.
  • SCHUSTER MJ, WU GY, WALTON CM, WU CH: Multicomponent DNA carrier with a vesicular stomatitis virus G-peptide greatly enhances liver-targeted gene expression in mice. Bioconjug Chem. (1999) 10(6):1075–1083.
  • WALTON CM, WU CH, WU GY: A DNA delivery system containing listeriolysin 0 results in enhanced hepatocyte-directed gene expression. World J. Gastroenterol. (1999) 5(6):465–469.
  • REINIS M, DAMKOVA M, KOREC E: Receptor-mediated transport of oligodeoxynucleotides into hepatic cells.Wrol. Methods (1993) 42(1):99–105.
  • WU GY, WU CH: Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. (1992) 267(18):12436–12439.
  • BARTHOLOMEW RM, CARMICHAEL EP, FINDEIS MA, WU CH, WU GY: Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks. J. Viral Hepat. (1995) 2(0:273–278.
  • WU CH, WU GY: Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines. Gastroenterology (1998) 114(6):1304–1312.
  • HOSTETLER KY, KORBA BE, SRIDHAR CN, GARDNER MF: Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice. Antiviral. Res. (1994) 24(1):59–67.
  • KORBA BA. XIE H, WRIGHT KN et al.: Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo. Hepatology (1996) 23(5):958–963.
  • BIJSTERBOSCH MK VAN BERKEL Uptake of lactosylated low-density lipoprotein by galactose-specific receptors in rat liver. Biochem. J. (1990) 270(1):233–239.
  • BIJSTERBORSCH MK, VAN BILT H, VAN BERKEL Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Biochem. Pharmacol. (1996) 52(1):113–121.
  • •Description of lactosylated synthetic HDL for liver targeting of antivirals.
  • KAWAKAMI S, MUNAKATA C, FUMOTO S, YAMASHITA F, HASHIDA M: Targeted delivery of prostaglandin E, to hepatocytes using galactosylated liposomes. J. Drug. Target. (2000) 8(3):137–142.
  • VRUEH RL, RUMP ET, VAN BILT E, et al.: Carrier-mediated delivery of 9-(2-phosphonylmethoxyethypadenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. Antimicrob. Agents. Chemother. (2000) 44(3):477–483.
  • BIJSTERBOSCH MK, YING C, DE VRUEH RL et al.: Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethypadenine against hepatitis B virus. MoL Pharmacol (2001) 60(3):521–527.
  • •Adefovir targeting to the liver.
  • BIESSEN EA, VALENTIJN AR, DE VRUEH RL et al.: Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethypadenine with improved pharmacokinetics and antiviral activity. FASEB J. (2000) 14(12):1784–1792.
  • ISHIHARA H, HAYASHI Y, HARA T, ARAIVIAKI Y, TSUCHIYA S, KOIKE K: Specific uptake of asialofetuin-tacked liposomes encapsulating interferon-gamma by human hepatoma cells and its inhibitory effect on hepatitis B virus replication. Biochem. Biophys. Res. Commun. (1991) 174(2):839–845.
  • LAMBROS MP, ABBAS SA, DUNN ST, RAJA T, PENTO T: Targeting hepatocytes with liposomal interferon-alpha: effect on metallothionein gene induction. Res. Commun. MoL Pathol Pharmacol (2002) 112(1-4):50–58.
  • BIJSTERBOSCH MK, MANOHARAN M, DORLAND R, VAN VEGHEL BIESSEN EA, VAN BERKEL Bis-cholesteryl-conjugated phosphorothioate oligodexynucleotides are highly selectively taken up by the liver. J. Pharmacol Exp. Ther. (2002) 302(2):619–626.
  • LEHMANN TJ, ENGELS JW: Synthesis and properties of bile acid phosphoramidites 5'-tethered to antisense oligodeoxynucleotides against HCV. Bioorg. Med. Chem. (2001) 9(7):1827–1835.
  • FIUME L, MATTIOLI A, BUST C, ACCORSI C: Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver. Gut (1984) 25(12):1392–1398.
  • FIUME L, BASSI B, BUST C, MATTIOLI SPINOSA G: Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-beta-D-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem. Pharmacol (1986) 35(6):967–972.
  • FIUME L, BUST C, DI STEFANO G et al:Liver targeting of adenine arabinoside monophosphate (ara-AMP) by coupling to lactosaminated human serum albumin. Ital. Gastroenterol (1995) 27(4):189–192.
  • PONZETTO A, FIUME L, FORZANI B et al.: Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepatology (1991) 14(1):16–24.
  • FIUME L, CERENZIA MR, BONINO F et al: Inhibition of hepatitis B virus replication by viclarabine monophosphate conjugated with lactosaminated serum albumin. Lancet (1988) 2(8601):13–15.
  • CERENZIA M, FIUME L, DE BERNARDI VENON et al: Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology (1996) 23(4):657–661.
  • •Report of a pilot clinical trial for targeted delivery of adenine arabinoside monophosphate by lactosaminated human albumin.
  • WANG H, ZHANG L, WANG X: Preliminary clinic observation on the inhibiton of HBV by receptor-targeted drug L-HAS-AraAMP. Zhonghua Shi Van He Lin Chuang Bing Du Xue Za Zhi (1998) 12(1):12–14.
  • FIUME L, STEFANO G, BUST C, MATTIOLI A: A conjugate of lactosaminated poly-L-lysine with adenine arabinoside monophosphate, administered to mice by intramuscular route, accomplishes a selective delivery of the drug to the liver. Biochem. Pharmacol (1994) 47(4):643–650.
  • STEFANO G, BUST C, MATTIOLI A, FIUME L: Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route. Biochem. Pharmacol (1995) 49(12):1769–1775.
  • FIUME L, STEFANO G, BUST C, et al.: Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Hepatology (1995) 22(4 Pt 0:1072–1077.
  • •Improvement of liver targeting carrier for intramuscular administration.
  • FIUME L, STEFANO G, BUST C et al: Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate. J. Hepatol (1997) 26(2):253–259.
  • STEFANO G, COLONNA FP, BONGINI A, BUST C, MATTIOLI A. FIUME L: Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Biochem. Pharmacol (197) 54(3):357–363.
  • •Ribavirin targeting to the liver.
  • STEFANO G, BIGNAMINI A, BUST C, COLONNA FP, FIUME L: Enhanced accumulation of ribavirin and its metabolites in liver versus erythrocytes in mice administered with the liver targeted drug. Ital. J. Gastroenterol. Hepatol. (1997) 29(5):420–426.
  • ZHONG S, WEN S, ZHANG D: Inhibition of HBV gene expression by antisense oligonucleotides using galactosylated poly(L-lysine) as a hepatotropic carrier. Zhonghua Shi Van He Lin Chuang Bing Du Xue Za Zhi (2001) 15(2):150–153.
  • ENRIQUEZ PM, JUNG C, JOSEPHSON L, TENNANT BC: Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity. Bioconjug. Chem. (1995) 6(2):195–202.
  • SUGINOSHITA Y, TABATA Y, MATSUMURA T et al.: Liver targeting of human interferon-beta with pullulan based on metal coordination. J. Control. Release (2002) 83(1):75–88.
  • JENSEN KD, KOPECKOVA P, KOPECEK J: Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. Bioconjug. Chem. (2002) 13(5):975–984.
  • DAVID A, KOPECKOVA P, RUBINSTEIN A, KOPECIK J: Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjugate Chem. (2001) 12:890–899.
  • AKAMATSU K, YAMASAKI Y, NISHIKAWA M, TAKAKURA Y, HASHIDA M: Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E(1) using lactosylated poly(L-glutamic hydrazide) as a carrier. Biochem. Pharmacol. (2001) 62(11):1531–1536.
  • TAKAHASHI H, ONISHI H, MACHIDAY: Glycyrrhetic acid-loaded microparticles: liver-specific delivery and herapeutic potential against carbon tetrachloride-induced hepatitis. J. Pharm. Pharmacol. (2004) 56(4):437–444.
  • WELCH PJ, TRITZ R, YET S, BARBER J, YU M: Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther. (1997) 4(7):736–743.
  • JI W, ST CW: Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. J. Viral Hepat. (1997) 4(3):167–173.
  • SCAGLIONI P, MELEGARI M, TAKAHASHI M, CHOWDHURY JR, WANDS J: Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology (1996) 24(5):1010–1017.
  • ZHANG J, YAMADA 0, SAKAMOTO T et al.: Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology (2004) 320(1):135–143.
  • VANDENDRIESSCHE T, THORREY L, NALDINI L et al.: Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood (2002) 100(3):813–822.
  • CHUAH MK, SCHIEDNER G, THORREYL et al.: Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood (2003) 101 (5) :1734–1743.
  • ZHANG Z, HE Q: Study on liver targeted valaciclovir polybutylcyanoacrylate nanoparticles. Yao Xue Xue Bao (1998) 33(9):702–709.
  • FATTAL E, VAUTHIER C, AYNIE I et al.: Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J. Control. Release (1998) 53(1-3):137–143.
  • SHIBUYA I, AKAIKE T, WATANABE Y: Design of a temporally and spatially controlled drug delivery system for the treatment of liver diseases in mice. Hepatology (2000) 32(61:1300–1308.
  • YAMADA T, IWASAKI Y, TADA H et al.: Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat. Biotechnol. (2003) 21(8):885–890.
  • ERION MD, VAN POELJE PD, MACKENNA DA et al.: Liver-targeted drug delivery using HepDirect Prodrugs. J. Pharm. Exp. Ther. (2005) 312(2):554–560.
  • •Novel HepDirect prodrug.
  • BUDKER V, ZHANG G, KNECHTLE S, WOLFF JA: Naked DNA delivered intraportally expresses efficiently in hepatocytes. Gene Ther. (1996) 3(7):593–598.
  • ZHANG G, VARGO D, BUDKER V, ARMSTRONG N, KNECHTLE S, WOLFF JA: Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum. Gene Ther. (1997) 8(15):1763–1772.
  • ZHANG G, BUDKER V, WOLFF JA: High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. (1999) 10(141735–1737.
  • •Description of systemic hydrodynamic gene delivery to the liver.
  • MCCAFFREY AP, MEUSE L, PHAM TT,CONKLIN DS, HANNON GJ, KAY MA: RNA interference in adult mice. Nature (2002) 418(6893):38–39.
  • EASTMAN SJ, BASKIN KM, HODGES BL et al.: Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum. Gene Ther. (2002) 13(17):2065–2077.
  • •Catheter-based procedure for hydrodynamic gene delivery to the liver.
  • ZHANG X, DONG X, SAWYER GJ, COLLINS L, FABRE JW: Regional hydrodynamic gene delivery to the rat liver with physiological volumes of DNA solution. J. Gene Med. (2004) 6(6):693–703.
  • YAMAGATA Y, IGA K, OGAWA Y: Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids. J. Control. Release (2000) 63(3):319–329.
  • YAMAGATA Y, YUASA Y, YAMAMOTO K et al.: Pharmacologic effect of recombinant human IFN-alpha, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2',5'-oligoadenylate synthetase activity in murine liver. J. Interferon Cytokine Res. (2000) 20(2):153–160.

Websites

  • http://www.who.int/mediacentre/ factsheets/fs204/en/ World Health Organization: Hepatitis B. Fact sheet No. 204 (Revised 2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.